Stock Research for VSTM


Featured Broker: Ally Invest

Get the due diligence for another stock.


VSTM Stock Chart & Research Data

The VSTM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VSTM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


VSTM Due diligence Resources & Stock Charts

The VSTM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View VSTM Detailed Price Forecast - CNN Money CNN View VSTM Detailed Summary - Google Finance
Yahoo View VSTM Detailed Summary - Yahoo! Finance Zacks View VSTM Stock Research & Analysis -

Stock Analysis

TradeIdeas View VSTM Trends & Analysis - Trade-Ideas Barrons View VSTM Major Holders - Barrons
NASDAQ View VSTM Call Transcripts - NASDAQ Seeking View VSTM Breaking News & Analysis - Seeking Alpha
Spotlight View VSTM Annual Report - OTC Report View VSTM OTC Short Report -
TradeKing View VSTM Fundamentals - TradeKing Charts View VSTM SEC Filings - Bar Chart
WSJ View Historical Prices for VSTM - The WSJ Morningstar View Performance/Total Return for VSTM - Morningstar
MarketWatch View the Analyst Estimates for VSTM - MarketWatch CNBC View the Earnings History for VSTM - CNBC
StockMarketWatch View the VSTM Earnings - StockMarketWatch MacroAxis View VSTM Buy or Sell Recommendations - MacroAxis
Bullish View the VSTM Bullish Patterns - American Bulls Short Pains View VSTM Short Pain Metrics -

Social Media Mentions

StockTwits View VSTM Stock Mentions - StockTwits PennyStocks View VSTM Stock Mentions - PennyStockTweets
Twitter View VSTM Stock Mentions - Twitter Invest Hub View VSTM Investment Forum News - Investor Hub
Yahoo View VSTM Stock Mentions - Yahoo! Message Board Seeking Alpha View VSTM Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for VSTM - Insider Cow View Insider Transactions for VSTM - Insider Cow
CNBC View VSTM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for VSTM - OTC Markets
Yahoo View Insider Transactions for VSTM - Yahoo! Finance NASDAQ View Institutional Holdings for VSTM - NASDAQ

Stock Charts

FinViz View VSTM Stock Insight & Charts - StockCharts View VSTM Investment Charts -
BarChart View VSTM Stock Overview & Charts - BarChart Trading View View VSTM User Generated Charts - Trading View

Latest Financial News for VSTM

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Wednesday December 05, 2018

Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its common stock to four employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.21 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on December 3, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting
Posted on Tuesday December 04, 2018

Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies

Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Posted on Monday December 03, 2018

Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from an investigator sponsored trial, led by Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center (MSK), evaluating duvelisib in combination with romidepsin in patients with relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) at the American Society of Hematology (ASH) 2018 Annual Meeting, taking place December 1-4, 2018, in San Diego. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.

New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
Posted on Monday December 03, 2018

NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.